Even_header_V22E18AU1-removebg-preview.png
Even_header_V22E18AU1-removebg-preview.png
11453696_xl_edited.jpg

29 June 2022, Wednesday ǀ 10:00 am to 12:00 pm (EDT)

Measures Taken for Improving Biosimilar Uptake and the
Potential Role of Healthcare Providers and Patients

Speakers' Presentations Available

ASBM Promo Banner.png

Keynote Presentation

Impact of biosimilars in the US healthcare system and the path forward 

Eric David Hargan, JD

Former United States Deputy Secretary of Health and Human Services

Wix header (2).png
Wix header (2).png
Wix header (2).png

Michael S ReillyEsq                      Ralph McKibbin                               Professor Philip J Schneider 
Executive Director                            MD, FACP, FACG, AGAF                  MS, FASHP, FASPEN, FFIP
Alliance for Safe Biologic                 President of the Pennsylvania           Professor at The Ohio State       Medicines                                         Society of Gastroenterology              University College of Pharmacy
                                                         Society of Gastroenterology
                                                         and the Digestive Disease
                                                         National Coalition

Wix header (1).png
Wix header.png
Wix header (1).png

Chad PettitMBA                            Andrew Spiegel, Esq                       Steven StranneMD, JD
Executive Director, Marketing          Executive Director.                            Partner, Foley Hoag LLP
Biosimilars Business Unit.               Global Colon Cancer                         Moderator
Amgen                                             Association                                   

First ASBM/GaBI Biosimilar Webinar

Biosimilars have been in the market for 16 years since its first launch in 2006 in Europe, currently, there are 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While more biosimilars entering the healthcare system, there remains the need for broader information share and regular discussions to clarify and alleviate the concerns of biosimilars use for physicians and patients, specifically on the issues of prescribing practice and switching of biosimilars.

 

In this online event, we discussed key elements contributing to the wide uptake of biosimilars in Europe and the US and physicians’ trust in prescribing and switching of biosimilars. Presentations of concrete examples and experiences on challenges and uptake policies of biosimilars in Europe and the current status of market access of and successful uptake measures implemented for biosimilars in the US allow us to evaluate the role of healthcare providers (physicians, pharmacists) and health policymakers in biosimilars use.

An academic clinician with specialty in gastroenterology, a pharmacist, a patient advocate and a market access expert shared their experience with biosimilars, highlighting successes and challenges, their perspectives on prescribing and switching of biosimilars and measures to increase biosimilar adoption, including the role of healthcare providers.

Enhanced knowledge on biosimilars use will help provide

more affordable treatment choices for patients.

Learning Objectives​​

  • To gain an insight on key elements contributing to the wide uptake of biosimilars in Europe and the US

  • To hear the physicians’ trust in prescribing and switching of biosimilars

  • To understand the challenges and uptake policies of biosimilars in Europe

  • To examine the current status of market access of and successful uptake measures implemented for biosimilars in the US

  • To recognize patients’ concerns in biosimilars use

  • To evaluate the role of healthcare providers (physicians, pharmacists) and health policymakers in biosimilars use

  • To identify educational needs to enhance knowledge on biosimilars use

calendar-icon-flat-design-calendar-date-date-picker-symbol-icon-design-line-square-png-cli

NEXT ONLINE EVENT!

ASBM–GaBI Biosimilar Webinar Series
This webinar is the first in a series.

The discussion will continue at the third webinar on ‘Ophthalmic Biosimilars’  in September 2022. More information will be available soon or contact us for more information!

Join the Club

Join our email list and get access to upcoming ASBM-GaBI webinars exclusive to our subscribers

Subscribe to Our Newsletter

Thanks for submitting!

Even header V22E18AU1.png
Even header V22E18AU1.png

This public webinar is hosted by the

Alliance For Safe Biologic Medicines (ASBM) and Generics and Biosimilars Initiative (GaBI).